We have previously shown that ASPP1 and ASPP2 are specific activators of p53; one mechanism by which wild-type p53 is tolerated in human breast carcinomas is through loss of ASPP activity. We have further shown that 53BP2, which corresponds to a C-terminal fragment of ASPP2, acts as a dominant negative inhibitor of p53 (ref. 1). Hence, an inhibitory form of ASPP resembling 53BP2 could allow cells to bypass the tumor-suppressor functions of p53 and the ASPP proteins. Here, we characterize such...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
If you are the owner of this record, you can report an update to it here: Report update to this record